Instalab
logoInstalab

9p21 Genotype (rs10757278)

Blood or Oral Swab Test
Learn about a common inherited contributor to coronary disease that cholesterol testing doesn't reveal.
4.9 (2,875 reviews)
Tested by Quest or GB Insights
Physician-reviewed results
Results in 21–28 business days
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get tested
Self-collect at home with the kit we mail you, or have a phlebotomist draw your blood at home or at a lab
Get results
Explained with clear next steps, no medical jargon

Should you take a 9p21 Genotype (rs10757278) test?

This test is most useful if any of these apply to you.

Concerned About Early Heart Disease in Your Family
Explore one inherited contributor to coronary risk while keeping your family history and current risk factors in view.
Reassured by Your Labs but Curious About Inherited Risk
Learn about a common genetic association that cholesterol testing cannot identify; its added treatment value is unproven.
Weighing How Much Genetic Testing Adds
Understand what a single-region result contributes before using genetic information in prevention decisions.
Living With Very High Inherited LDL
Explore an additional risk association while keeping early treatment of familial hypercholesterolemia the priority.

About 9p21 Genotype (rs10757278)

Your 9p21 genotype describes inherited DNA in a region of chromosome 9 associated with coronary artery disease. The association is among the most consistently replicated findings in heart disease genetics. Studies comparing people with and without coronary disease commonly find roughly 25% higher odds of disease with one higher-risk copy and roughly 45% to 50% higher odds with two.

That association often remains after accounting for cholesterol, blood pressure, smoking, and diabetes. But adding this single genetic region to standard risk assessment usually improves prediction very little. Its association with disease is well established; using the result to choose earlier scans, different medications, or stricter cholesterol goals has not been shown to improve health outcomes.

What Your Result Reports

The test examines inherited DNA from white blood cells collected in a blood draw. It identifies common single-letter DNA differences in the 9p21 region, including rs10757278 and rs1333049. These differences are called single-nucleotide polymorphisms, or SNPs. The two markers are often inherited together, particularly in populations of European ancestry, and usually identify the same underlying risk pattern.

You inherit one copy of chromosome 9 from each parent. At each tested position, you therefore have zero, one, or two copies of the higher-risk version. These versions are common, and carrying one is different from having a rare mutation that causes a strongly inherited disorder.

Risk copies at each positionUsual genotype notationInterpretation
Noners10757278 AA or rs1333049 GGNeither copy has the higher-risk letter at that position; coronary disease and other inherited risks remain possible.
Oners10757278 AG or rs1333049 GCOne copy has the higher-risk letter, associated with a modest increase in coronary disease susceptibility.
Twors10757278 GG or rs1333049 CCBoth copies have the higher-risk letter, generally associated with greater susceptibility than one copy.

The variant identifier matters as much as the letters. GG represents two risk copies at rs10757278 but none at rs1333049 in the notation above. Because these markers usually identify the same inherited stretch of DNA, their copy counts shouldn't be added together as separate risks.

How the Region May Influence Plaque

The common coronary risk markers lie in DNA that doesn't provide instructions for making a protein. Parts of this region overlap ANRIL, which produces RNA involved in regulating gene activity. Nearby genes, including CDKN2A and CDKN2B, help control cell division.

Studies of human blood cells, heart tissue, and artery tissue have linked risk variants to changes in ANRIL and other gene activity. Laboratory experiments using human artery muscle cells also support effects on how these cells behave. The findings vary by cell type and by the form of ANRIL examined, so they don't establish one simple sequence in which every risk copy switches off the same genes and makes plaque grow.

The evidence supports a role in the development of artery disease beyond conventional cholesterol pathways. It doesn't establish that cholesterol, blood pressure, or inflammation markers are always unchanged in carriers.

Coronary Artery Disease

The strongest evidence concerns coronary artery disease. Plaque in the heart's arteries can restrict blood flow and contribute to angina and heart attacks. Studies have examined both the markers reported by this test and nearby markers that are frequently inherited with them.

Who was studiedWhat was comparedWhat was found
168,209 people initially without coronary heart disease across 16 studiesEach additional risk copy, using several closely linked 9p21 markersA 19% higher rate of a first coronary event during follow-up.
22,129 initially healthy white women followed for about 10 yearsTwo risk copies versus none at the related marker rs10757274A modestly higher rate of cardiovascular events after adjustment for conventional risk factors.
2,742 initially healthy middle-aged British men followed for 15 yearsTwo risk copies versus none at the related marker rs10757274A 60% higher rate of coronary heart disease after adjustment for conventional risk factors and family history.

These are relative comparisons within studied populations. They aren't percentage-point increases in your personal chance of disease, and the estimates differ with the population, outcome, and marker examined.

A Swedish study of 24,777 people found a similar association using another linked marker, rs4977574: each risk copy was associated with a 17% higher rate of cardiovascular disease. Despite that association, adding the marker did not meaningfully improve clinical risk prediction.

The association has generally been stronger in studies of early-onset coronary disease. A pooled analysis of 47 datasets found a larger effect when disease developed at younger ages. This supports a contribution to early susceptibility, but it doesn't establish that testing young adults changes their outcomes.

First Events and Events After Coronary Disease

Once coronary disease is established, the result adds little information about a subsequent heart attack. A large collaboration involving 103,357 people of European ancestry found no clear association with later coronary death or heart attack. An earlier pooled analysis and a Texas registry reached similar conclusions. A smaller study after an acute coronary syndrome reported a short-term association, but larger pooled studies did not confirm it.

There is evidence linking the region to the extent and progression of coronary disease. A combined analysis of 33,673 people who underwent coronary imaging found an association with disease in multiple arteries. In a separate study, 308 people had repeat angiograms; those with two rs10757278 risk copies had about threefold higher odds of meeting the study's definition of progression. That estimate describes the odds of progression, not a threefold increase in its speed.

The large study of established coronary disease also found that each rs1333049 risk copy was associated with 7% higher odds of a subsequent procedure to restore coronary blood flow. Together, these findings support a role in plaque development. They don't make the genotype a reliable measure of your current plaque burden or its future growth rate.

Other Vascular Associations

  • Ischemic stroke: studies have found a modest association, strongest for strokes involving atherosclerosis in large arteries. Atherosclerosis is the buildup of plaque in artery walls. The association has been less consistent for other stroke mechanisms.
  • Aneurysms: rs10757278 has also been associated with abdominal aortic and intracranial aneurysms. An aneurysm is a bulge in a weakened artery wall. These associations extend beyond plaque formation and do not establish a screening program based on this genotype.
  • Artery mechanics: a study of 400 older adults examined related 9p21 markers and found lower abdominal aortic stiffness in male risk-allele carriers. It did not show that these variants consistently make arteries stiffer.
  • Heart failure: an ARIC study using the related marker rs10757274 found higher heart failure risk in white participants with two risk copies. The association persisted after accounting for recognized coronary disease, although unrecognized coronary disease could still have contributed.
  • Coronary calcium: a study of 1,688 Korean adults linked another marker in the region, rs10757272, to greater coronary calcification. This is supporting evidence about the region, not a direct estimate for the two markers reported here.

Blood Sugar and Other Conditions

In a study of 1,626 young adults, several 9p21 risk variants were associated with higher fasting insulin in women but not men. The association was not statistically clear among women using hormonal contraceptives. Because measurements were taken at one point in time, the study couldn't establish that the variants caused insulin resistance or that contraceptives changed their effect.

Other variants in the wider 9p21 region have associations with type 2 diabetes and several cancers. Those findings involve different genetic changes and cannot be inferred from a coronary risk result.

Why Ancestry Changes Interpretation

The coronary disease association is well replicated in populations of European ancestry and has also been found in Asian and Hispanic populations. The frequencies of individual variants, the patterns in which they are inherited together, and the size of their associations differ across populations.

Large studies have found substantially different patterns in people with African ancestry. Some combinations of variants that carry the strongest association in European ancestry are uncommon on chromosomes of African ancestry. Individual risk letters can still be present. A result should therefore be interpreted with evidence relevant to your ancestry, and a zero-copy result cannot exclude inherited cardiovascular risk.

What It Adds to a Standard Risk Assessment

Standard cardiovascular risk assessments combine factors such as age, cholesterol, blood pressure, smoking, and diabetes. In the large study of women, adding a 9p21 marker barely changed the model's ability to distinguish those who later had an event from those who did not. The Swedish study also found little practical improvement.

In the British men's study, adding the marker changed risk categories for some participants, but the improvement in the model's ability to distinguish future cases was not statistically clear. Moving someone into a different category does not by itself show that the new category leads to better treatment decisions.

You can use the result as additional information about inherited susceptibility. There is no validated rule that turns one or two risk copies into a particular cholesterol goal, medication choice, or imaging schedule. A strong family history, measured lipoproteins, and evidence of existing disease remain important even when this result is reassuring.

Risk in Different Settings

Familial hypercholesterolemia causes very high LDL cholesterol from birth. In a study of 725 people with genetically confirmed familial hypercholesterolemia, each risk copy of a different marker in the 9p21 region, rs1333047, was associated with 42% higher odds of atherosclerotic cardiovascular disease. This supports an additional inherited contribution to risk, but it does not establish a treatment strategy based on the markers in this test. Familial hypercholesterolemia already provides a strong reason for early cholesterol treatment.

Diet may modify the association. Across the INTERHEART and FINRISK studies, people with diets richer in vegetables and fruit had a weaker association between 9p21 variants and cardiovascular disease. These were observational findings. They support a possible interaction but do not prove that a particular diet cancels the genetic contribution to risk.

Polygenic risk scores combine information from many variants across the genome. Early findings from the PROACT trials showed that selecting people with high polygenic scores could identify coronary plaque in some whose conventional risk estimates were low. Those findings concern a combined score and do not establish the same benefit for this single-region test.

When Results Can Be Misleading

  • Limited coverage: a zero-copy result means the tested higher-risk versions weren't found. It does not rule out other coronary risk variants, inherited high lipoprotein(a), or familial hypercholesterolemia.
  • Ancestry: the same marker may identify an underlying risk pattern more accurately in one ancestry group than another. Estimates from European populations should not automatically be applied to everyone.
  • Uncertain findings from broader testing: this targeted test reports known common variants. If a separate sequencing report lists a variant of uncertain significance, its health effect is unresolved and it should not be treated as a confirmed coronary risk finding.
  • Consumer reports and conflicting calls: reports can examine different positions or use different DNA-letter conventions. A disagreement should be checked against the exact variant and reporting convention. If the actual genotype remains disputed, confirmation using an independent clinical method may be appropriate.
  • Acquired changes and donor DNA: changes found only in tumor cells are different from inherited coronary risk variants. A donor stem-cell or bone-marrow transplant can also make blood DNA reflect the donor's genotype; an appropriate source of your own DNA is needed for inherited testing in that situation.

One-Time Result

Your inherited genotype is permanent, so a reliable result does not need routine repetition. Its interpretation can be updated as evidence changes without collecting another sample.

Ongoing monitoring concerns your cardiovascular risk factors. If you take cholesterol-lowering medication, lipid testing is generally repeated 4 to 12 weeks after starting or changing treatment and periodically after that, often every 3 to 12 months depending on your response. Without treatment, the interval depends on your risk and previous results. The 9p21 result alone does not establish a need for more frequent testing.

How the Result Fits Into Prevention

Zero risk copies leave other inherited and acquired risks in place. One or two copies add information about susceptibility, but neither result establishes that you have plaque or will develop a heart attack.

Prevention decisions should integrate your family history, blood pressure, lipid results, smoking, diabetes status, and any known coronary disease. A result can be part of that discussion, but prescribing treatment or ordering a scan solely because of the copy count goes beyond demonstrated clinical utility.

If you already have coronary disease, its diagnosis provides the reason for intensive prevention regardless of this genotype. A strong family history may also warrant evaluation for a more consequential inherited condition, even when no tested 9p21 risk copies are present.

Frequently Asked Questions

References

48 studies
  1. Kenneth Chan, Riyaz S. Patel, Paul J. Newcombe, Christopher P. Nelson, Atif Qasim, Stephen E. Epstein, Et Al.Journal of the American College of Cardiology2013
  2. Heribert Schunkert, Anika Götz, Peter S. Braund, Ralph E. Mcginnis, David-alexandre Trégouët, Massimo Mangino, Et Al.Circulation2008
  3. Robert Roberts, Alexandre F.R. StewartClinical Chemistry2011
  4. Michael S. Cunnington, Mauro Santibanez-koref, Bongani M. Mayosi, John Burn, Bernard D. KeavneyPLoS Genetics2010
  5. Sara Mahdavi, Katie Rosychuk, David J.A. Jenkins, Andrew J. Percy, Christoph H. Borchers, Ahmed El-sohemyNutrients2025

9p21 Genotype (rs10757278) Testing Options

$185

Learn about one inherited contributor to heart disease and how it fits with your other risk factors.

Includes 2 biomarkers:
9p21 Genotype (rs10757278)9p21 Genotype (rs1333049)
$499

Screens 140+ genes linked to inherited cholesterol disorders and other hidden drivers of heart disease risk.

162 biomarkers
FSA/HSA eligible
No Rx needed
HIPAA compliant